Foliar Nutrients, Inc. – Trademark Portfolio

Entity Type: 03

Foliar Nutrients, Inc. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include MEGA-PHOS and LEXX-A-PHOS. The owner is based in Cairo, GA.

320 1st Avenue, N.E.

Cairo, GA 31728

12 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Foliar Nutrients, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (8 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (5 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does Foliar Nutrients, Inc. have?

Foliar Nutrients, Inc. has 12 U.S. trademarks filed with the USPTO. Of these, 3 registered, 8 abandoned, 1 cancelled.

What trademark classes does Foliar Nutrients, Inc. file in?

Foliar Nutrients, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Foliar Nutrients, Inc.'s most well-known trademarks?

Foliar Nutrients, Inc.'s registered trademark portfolio includes well-known marks such as MEGA-PHOS and LEXX-A-PHOS. These are among 3 currently registered trademarks in the portfolio.

What is Foliar Nutrients, Inc.'s trademark registration success rate?

Foliar Nutrients, Inc. has a 25% trademark registration rate, with 3 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.